This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Article abstract Interferon beta (IFNβ) reduces the relapse rate, disease activity as measured by serial MRI scanning, and disease progression of MS. Therapy with IFNβ may be associated with a number of adverse reactions. Relatively frequent side effects include flu-like symptoms, transient laboratory abnormalities, menstrual disorders, and increased spasticity. Dermal injection site reactions occur after subcutaneous application of IFNβ-1b and IFNβ-1a. Possible side effects of IFNβ include various autoimmune reactions, capillary leak syndrome, anaphylactic shock, thrombotic-thrombocytopenic purpura, insomnia, headache, alopecia, and depression. We discuss the mechanisms and management of the different side effects of IFNβ.
- Received March 19, 1999.
- Accepted June 29, 1999.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Flu-like symptoms.
- Increased spasticity and other functional deteriorations.
- Laboratory abnormalities.
- Mood alterations.
- Injection site complications.
- Occurrence of concomitant autoimmune diseases.
- Other rare potential side effects.
- Miscellaneous organ-specific potential side effects.
- Effects of neutralizing antibodies on IFN-related side effects.
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Alert Me
Recommended articles
Cross-sectional study assessing long-term safety of interferon-β-1b for relapsing-remitting MS
Randomized, comparative study of interferon β-1a treatment regimens in MS
Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
Risk of Alzheimer's disease and duration of NSAID use